Want to see AEON full AI Analyst Report?
Top Page
AEON Biopharma
(NYSE MKT:AEON)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.64
▼(-41.82% Downside)
Action:Reiterated
Date:06/18/26
The score is driven primarily by weak financial performance (no revenue, recurring losses, cash burn, and negative equity) and bearish technicals (trading below key moving averages with negative MACD). Valuation is constrained by losses (negative P/E), and corporate events add risk due to exchange noncompliance and potential delisting.
Positive Factors
Focused clinical-stage platform
AEON’s concentrated clinical-stage focus on botulinum toxin therapies and lead program ABP-450 creates a clear strategic objective. A successful clinical/regulatory outcome could produce a high-margin specialty asset, attract partners, and leverage platform know-how across indications, supporting durable value creation if development milestones are met.
Negative Factors
No revenue and recurring losses
AEON has no operating revenue and posted a large TTM net loss, making the business fully dependent on external capital. Persistent losses erode reserves and require frequent financing, increasing dilution risk and creating long-term uncertainty unless clinical programs lead to partner deals or successful commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical-stage platform
AEON’s concentrated clinical-stage focus on botulinum toxin therapies and lead program ABP-450 creates a clear strategic objective. A successful clinical/regulatory outcome could produce a high-margin specialty asset, attract partners, and leverage platform know-how across indications, supporting durable value creation if development milestones are met.
Read all positive factors
AEON Biopharma (AEON) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$18.92M
Dividend YieldN/A
Average Volume (3M)273.24K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS Growth-101.45%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.03
Shares Outstanding26,307,210
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-229.00
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$16.30M
AEON Biopharma Business Overview & Revenue Model
Company Description
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botuli...
How the Company Makes Money
null...
AEON Biopharma Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
6
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -24.07M | -16.22M | -27.73M | -52.74M | -52.49M | -36.88M |
| Net Income | -60.11M | -39.22M | 42.01M | -384.63M | -52.56M | -55.64M |
Balance Sheet | ||||||
| Total Assets | 8.63M | 5.56M | 3.14M | 6.84M | 10.78M | 6.44M |
| Cash, Cash Equivalents and Short-Term Investments | 6.24M | 3.01M | 13.00K | 5.16M | 9.75M | 5.13M |
| Total Debt | 2.63M | 35.74M | 12.96M | 278.00K | 131.53M | 86.89M |
| Total Liabilities | 25.38M | 60.59M | 31.71M | 159.89M | 281.19M | 230.26M |
| Stockholders Equity | -16.75M | -55.03M | -28.57M | -153.04M | -287.50M | -234.94M |
Cash Flow | ||||||
| Free Cash Flow | -12.04M | -17.31M | -20.29M | -47.83M | -35.89M | -28.60M |
| Operating Cash Flow | -12.04M | -17.31M | -20.29M | -47.83M | -35.58M | -28.43M |
| Investing Cash Flow | 0.00 | -4.00K | 0.00 | 0.00 | -306.00K | -170.00K |
| Financing Cash Flow | 7.83M | 20.30M | 15.15M | 14.00M | 40.51M | 13.56M |
AEON Biopharma Technical Analysis
Negative
1.10
Price Trends
0.82
Negative
0.93
Negative
0.95
Negative
Market Momentum
-0.03
Negative
47.02
Neutral
92.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Negative. The current price of 1.1 is above the 20-day moving average (MA) of 0.71, above the 50-day MA of 0.82, and above the 200-day MA of 0.95, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 47.02 is Neutral, neither overbought nor oversold. The STOCH value of 92.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEON.
AEON Biopharma Risk Analysis
AEON Biopharma disclosed 61 risk factors in its most recent earnings report. AEON Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AEON Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $5.90M | -0.13 | -684.86% | ― | ― | 95.40% | |
47 Neutral | $7.48M | -0.30 | -341.23% | ― | ― | 71.83% | |
42 Neutral | $6.37M | -4.05 | -9.02% | ― | ― | ― | |
41 Neutral | $18.92M | -0.15 | 0.02% | ― | ― | -101.45% | |
| ― | $6.03M | -4.25 | ― | ― | ― | ― |
* Healthcare Sector Average
AEON
AEON Biopharma
0.72
-0.12
-14.40%
IMNN
Imunon
1.78
-8.65
-82.94%
XTLB
XTL Biopharmaceuticals Sponsored ADR
2.73
-2.07
-43.13%
APM
Aptorum Group
0.78
-0.14
-15.00%
RNAZ
TransCode Therapeutics
6.21
-2.08
-25.09%
AEON Biopharma Corporate Events
Executive/Board ChangesShareholder Meetings
AEON Biopharma shareholders approve directors and auditor slate
Positive
Jun 17, 2026
AEON Biopharma, Inc. held its Annual Meeting of Stockholders on June 17, 2026, at which shareholders elected Marc Forth and Seongsoo Park as Class III directors to serve three-year terms expiring at the 2029 annual meeting. Shareholders also ratif...
Business Operations and StrategyRegulatory Filings and Compliance
AEON Biopharma Releases Updated Investor Relations Presentation
Neutral
May 14, 2026
On May 14, 2026, AEON Biopharma, Inc. made a new corporate presentation available in the investor relations section of its website, which management may also use in future meetings with investors and other stakeholders. The company emphasized that...
Delistings and Listing ChangesRegulatory Filings and Compliance
AEON Biopharma Receives Additional NYSE American Noncompliance Notice
Negative
Apr 3, 2026
On March 31, 2026, AEON Biopharma received an additional notice from NYSE American that it is not in compliance with Section 1003(a)(ii), which requires at least $4 million in stockholders’ equity when a company has losses in three of its fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.